Omeros stock fell 12.03% to $16.53 in intraday trading on October 16, 2026, after a European Medicines Agency committee reaffirmed its negative opinion on narsoplimab. The setback leaves the company pursuing alternative patient-access arrangements in Europe while continuing to sell the treatment as YARTEMLEA in the United States.
Key Takeaways
- The European committee maintained its negative opinion after re-examining its June 2026 decision.
- Shares were down $2.26 at the reported intraday snapshot, not a confirmed closing price.
- Omeros is working toward reimbursed named-patient access where permitted while U.S. commercialization continues.
Table of Contents
- Omeros stock retreats after re-examination outcome
- U.S. sales continue despite the European setback
- Patient-access plans remain separate from authorization
- Conclusion
Omeros stock retreats after re-examination outcome
The Committee for Medicinal Products for Human Use, known as CHMP, issued another negative opinion on the marketing authorization application for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA.
Omeros’ October 16 regulatory update confirmed that the decision followed a re-examination of the committee’s original negative opinion adopted in June 2026. The review therefore did not reverse the earlier unfavorable outcome.
The share-price decline followed the announcement. Omeros traded below both its previous close of $18.79 and its opening price of $17.84, although the snapshot does not establish a final session loss.
| Item | Details |
|---|---|
| Trading venue | Nasdaq, ticker OMER |
| Intraday range | $15.89–$17.94 on October 16, 2026 |
| Volume at snapshot | 1.43 million shares, versus average volume of 1.70 million |
| 52-week range | $6.24–$21.24 |
U.S. sales continue despite the European setback
The European outcome contrasts with the drug’s U.S. status. The Food and Drug Administration approved narsoplimab under the YARTEMLEA brand in December 2025 for TA-TMA patients aged two years and older.
Omeros continues to commercialize YARTEMLEA through its own U.S. field force. The company said it plans to license European Union commercialization rights to a third party if EU marketing authorization is granted; that arrangement remains conditional on approval.
The distinction matters for the business: the negative European opinion concerns a separate authorization process, rather than a withdrawal of the existing U.S. approval.
Patient-access plans remain separate from authorization
Chief executive Gregory A. Demopulos expressed disappointment with the re-examination process and outcome. Omeros said it was working to enable fully reimbursed, named-patient access for TA-TMA patients where permitted in Europe and other regions. That is an access initiative in progress, not an announced European marketing approval.
Separately, Omeros said increasing U.S. commercial demand had prompted it to notify CHMP of its intention to terminate its YARTEMLEA compassionate-use program. Patients already receiving treatment through that program will be supplied with enough medicine to complete their treatment courses, the company said.
Conclusion
The re-examination left the European regulatory setback unresolved. The next developments to watch are implementation of Omeros’ stated patient-access plans and the compassionate-use transition, alongside continued U.S. commercialization.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
